Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma

NCT07097935 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Clear Cell Renal Cell Carcinoma

Interventions

DRUG: HS-10516 + Lenvatinib

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.